A Phase 3 interventional study of Methylprednisolone and Placebos in Chronic Obstructive Pulmonary Disease, sponsored by Versailles Hospital. Completed at 23 sites in France. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Versailles Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France — 71 open to participants now, 81 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · France.
Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, this one is the 90th largest by enrollment of the 286 interventional ones that give a count, is one of 21 that started in 2021, is one of 83 in phase 3, and was the 266th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →71 of the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France are open now. Recruiting first, the newest first:
Fondation Hôpital Saint-Joseph · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
Eli Lilly and Company · Sites in France, United States, Argentina and 15 more countries
Ages 40–75
CHU de Reims · Sites in France
Ages 18+
Groupe Hospitalier du Havre · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
406 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 84 · Phase 4 20
First in 2000; this study’s year is marked. 21 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 440 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 138 across the 286 interventional studies, 100 across the 119 observational. Of the 299 that completed or were terminated, 70 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
136 of 406 have an industry lead sponsor. The 10 most frequent:
Versailles Hospital is the lead sponsor of 74 studies on the registry; 16 are open to participants now.
Versailles Hospital has 2 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
16 of the studies in Pulmonary Disease, Chronic Obstructive with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT05844462Phase 3Assistance Publique - Hôpitaux de ParisTadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease | 2027-10 |
| NCT07125989Centre Hospitalier Universitaire de Saint EtienneEffect of Exercise Ventilatory Support Pressure on Endurance in Patients With Severe Chronic Obstructive Pulmonary Disease - AVE-BPCO | 2027-01 |
| NCT04339270University Hospital, MontpellierChronic Airway Disease, Mucus Rheology and Exacerbations | 2027-02 |
| NCT06653933University Hospital, GrenobleStudy of Sleep Quality in the Intensive Care Unit and Association with Weaning from Invasive Ventilation in Patients with Chronic Obstructive Bronchopneumopathy. | 2027-02-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to determine if the systemic (intravenous) administration of corticosteroids, as compared to placebo, increases the number of ventilator-free days (VFD) and alive at day 28 in COPD patients admitted to an ICU, a step-up unit or a respiratory care unit for an acute on chronic respiratory failure (ACRF) requiring ventilatory support, either invasive or non-invasive.
The criteria were revised on the registry on Oct 23, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Strongly suspected or documented , defined by the presence of the following criterias:
Severe acute exacerbation, defined by the presence of the two following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Methylprednisolone
Drug: Placebos
In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.
in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
the number of ventilator-free days (VFD) and alive at day 28.
To determine if the systemic administration of corticosteroids, as compared to placebo, increases the number of ventilator-free days (VFD) and alive at day 28 in COPD patients admitted to an ICU, a step-up unit or a respiratory care unit for an ACRF requiring ventilatory support, either invasive or non-invasive.
Time frame: day 28
NIV failure rate
NIV failure rate, defined by intubation within day 7
Time frame: day 7
Duration of NIV and of invasive mechanical ventilation
Duration of Non Invasive Ventilation and of invasive mechanical ventilation
Time frame: at day 90
Circulatory and renal support-free days and alive at day 28
Circulatory and renal support-free days and alive at day 28
Time frame: at day 28
Severe hyperglycemia requiring intravenous insulin during the five first days
Severe hyperglycemia requiring intravenous insulin during the five first days
Time frame: during the five first days
Gastro-intestinal bleeding
acute loss of 2 g/dL of hemoglobin requiring red blood cell transfusion or gastroscopic evaluation
Time frame: between inclusion and day 28
Uncontrolled arterial hypertension
unusual hypertension requiring to introduce/add antihypertensive medication (compared to usual medications)
Time frame: between inclusion and day 28
ICU acquired weakness (MRC-score < 48/60) assessed on day 28 or at the time of ICU discharge
Intensive Care Unit acquired weakness (MRC-score \< 48/60) assessed on day 28 or at the time of ICU discharge
Time frame: at day 28
ICU-acquired infections (especially Ventilator-Associated Pneumonia)
Intensive Care Unit -acquired infections (especially Ventilator-Associated Pneumonia)
Time frame: at the time of ICU discharge or day 90
Length of ICU and hospital stay
Length of ICU and hospital stay
Time frame: at day 90
ICU and hospital mortality
ICU and hospital mortality
Time frame: between inclusion and day 28 or day 90
Day 28 and Day 90 mortality
Day 28 and Day 90 mortality
Time frame: at Day 28 and Day 90
Standardized mortality ratio (SMR)
Standardized mortality ratio (SMR)
Time frame: between inclusion and day 90
Number of new exacerbation(s)/hospitalization(s) between hospital discharge and Day 90
Number of new exacerbation(s)/hospitalization(s) between hospital discharge and Day 90
Time frame: at day 90
Dyspnea (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score
Dyspnea (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score
Time frame: at day 90
respiratory comfort (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score
respiratory comfort (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score
Time frame: at day 90
Ran from Oct 2021 to primary completion in Nov 2024, 36 months.
Of 33 non-industry phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 56. This study's 36 months is close to that.
Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2025 → Nov 2024 and completion Mar 2026 → Apr 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylprednisolone
Pulmonary Disease, Chronic Obstructive →
Versailles Hospital